Soliris is a breakthrough, potentially lifesaving treatment for two rare blood diseases, affecting about 180 patients in Canada. The board, which has not held an excessive-price hearing since 2012, said it had demanded the U.S.-based firm lower the price and pay back revenue it made above the cap.